New financial analysis reveals significant savings realized from CYP2C19 testing

Twenty lives and $440,000 over a year. For every 1,000 patients. That’s what CYP2C19 pharmacogenetic testing could save if used to help prescribe clopidogrel (Plavix), prasugrel or ticagrelor to specific cardiac patients. A budget analysis found that a genotype-guided approach for acute coronary syndrome patients (ACS) undergoing percutaneous coronary intervention (PCI) for one year saved 20 lives and $444,852 in … Read More

The Pharmacist’s Corner: Clopidogrel dosing and genetic variations

By Rachel Sass, PharmD Should providers increase the clopidogrel dose in patients with decreased functioning CYP2C19 enzymes? Clopidogrel (Plavix) is one of the most well studied medications in pharmacogenetics.  Clopidogrel is a prodrug, meaning that it needs to be converted to an active metabolite in the body to have an effect. This metabolizing process occurs in part via the polymorphic … Read More